Published in Medical Letter on the CDC and FDA, July 12th, 2009
"Many in the distribution chain have expressed concerns over the potential for liability when countermeasures are distributed in accordance with large-scale response plans. This is of particular concern if the medical countermeasure involved has not been approved, cleared, or licensed by the US Food and Drug Administration (FDA)," wrote C. Maher and colleagues, Food & Drug Administration.
The researchers concluded: "This article discusses legal and regulatory options for countermeasure...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA